Hasil Pencarian - Peter Probst

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial.

    Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial. oleh Eric J Tarcha, Chelsea M Olsen, Peter Probst, David Peckham, Ernesto J Muñoz-Elías, James G Kruger, Shawn P Iadonato

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    271 Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages

    271 Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages oleh Peter Probst, Huyen Dinh, Sam Lam, Valerie Wall, Darbie Whitman, Tom Graddis, Myriam Bouchlaka, Randi Simmons, Meghan Zuck, Ray Fox, Kamal Puri

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    262 Preclinical characterization of humanized anti-siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression

    262 Preclinical characterization of humanized anti-siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression oleh Lauren Loh, Peter Probst, Huyen Dinh, Sam Lam, Valerie Wall, Francisco Zapata, Darbie Whitman, Ramya Chandrasekaran, Texia Loh, Tom Graddis, Myriam Bouchlaka

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    276 Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression

    276 Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression oleh Lauren Loh, Peter Probst, Huyen Dinh, Sam Lam, Valerie Wall, Francisco Zapata, Ramya Chandrasekaran, Texia Loh, Tom Graddis, Myriam Bouchlaka, Meghan Zuck, Kamal Puri

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response

    519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response oleh Peter Probst, Kevin Green, Huyen Dinh, Francisco Zapata, Darbie Whitman, Tom Graddis, Myriam Bouchlaka, Meghan Zuck, Ray Fox, Tatyana Pisarenko, Elsa L Hay, Gajendra Naika, Jacob Heit, Kamal D Puri

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses

    494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses oleh Peter Probst, Kevin Green, Huyen Dinh, Francisco Zapata, Darbie Whitman, Tom Graddis, Meghan Zuck, Ray Fox, Myriam N Bouchlaka, Tatyana Pisarenko, Elsa L Hay, Gajendra Naika, Jacob Heit, Kamal D Puri

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation.

    A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation. oleh Michelle L Scalley-Kim, Bruce W Hess, Ryan L Kelly, Anne-Rachel F Krostag, Kurt H Lustig, John S Marken, Pamela J Ovendale, Aaron R Posey, Pamela J Smolak, Janelle D L Taylor, C L Wood, David L Bienvenue, Peter Probst, Ruth A Salmon, Daniel S Allison, Teresa M Foy, Carol J Raport

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: